Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HK1 | P19367 | 1/20 | 0.39 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PRNP | P04156 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174233 | 0.90 | HSP90AB1 (0.49) | HSP90AB1GAAALDH1A1GFERL3MBTL1 | |
| SCHEMBL11467699 | 0.85 | HSP90AB1 (0.50) | HSP90AB1GAAALDH1A1GFERL3MBTL1 | |
| SCHEMBL2331533 | 0.85 | HSP90AB1 (0.43) | HSP90AB1GAAALDH1A1GFERMEN1 | |
| SCHEMBL2176876 | 0.84 | CYP11B1 (0.51) | HSP90AB1GAAALDH1A1GFERMAPT | |
| SCHEMBL2175327 | 0.84 | HSP90AB1 (0.49) | HSP90AB1GAAALDH1A1GFERL3MBTL1 | |
| SCHEMBL11477653 | 0.83 | HSP90AB1 (0.42) | HSP90AB1GAAALDH1A1GFERL3MBTL1 | |
| SCHEMBL2175522 | 0.83 | HSP90AB1 (0.45) | HSP90AB1GAAALDH1A1GFERMEN1 | |
| SCHEMBL2171172 | 0.82 | HSP90AB1 (0.53) | HSP90AB1GAAALDH1A1GFERMEN1 | |
| SCHEMBL27822168 | 0.81 | AKR1B1 (0.51) | GAAMAPTLMNAHSD17B10HPGD | |
| SCHEMBL11471175 | 0.81 | GAA (0.51) | HSP90AB1GAAALDH1A1GFERL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2791111-B1 | [4-(PIPERIDIN-4-YL)-NAPHTHALEN-2-YL]-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS FOR THE TREATMENT OF RESPIRATORY DISORDERS | HOFFMANN LA ROCHE (CH) | 2017-01-18 | — | — | EP | disclosed |
| EP-2791111-A1 | PIPERIDINYL NAPHTHYLACETIC ACIDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-22 | — | — | EP | disclosed |
| US-8642629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2358677-B1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| EP-2358677-B1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| WO-2013087544-A1 | PIPERIDINYL NAPHTHYLACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-20 | — | — | WO | disclosed |
| US-20130150407-A1 | PIPERIDINYL NAPHTHYLACETIC ACIDS | HOFFMANN-LA ROCHE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2346819-B1 | NAPHTHYLACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2013-04-10 | — | — | EP | disclosed |
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-05-20 | — | — | US | disclosed |
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-05-20 | — | — | US | disclosed |
| US-4207241-A | ANALGESICS, ANTIPYRETICS, ANTIINFLAMMATORY AGENTS AND ANTIPRURITIC AGENTS | SYNTEX CORPORATION (US) | 1980-06-10 | — | — | US | disclosed |
| US-4097674-A | ANTIINFLAMMATORY, ANTIPYRETIC, ANTIPRURITIC AGENTS, ANALGESICS | SYNTEX CORPORATION (US) | 1978-06-27 | — | — | US | disclosed |
| US-4051233-A | ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC, ANTIPRURITIC | SYNTEX CORPORATION (US) | 1977-09-27 | — | — | US | disclosed |
| US-4001301-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS, ANTI-PRURITIC | SYNTEX CORPORATION (PM) | 1977-01-04 | — | — | US | disclosed |
| US-3998966-A | Anti-inflammatory, analgesic, anti-pyretic and anti-pruritic 6-substituted 2-naphthyl acetic acid derivative-containing compositions and methods of use thereof | SYNTEX CORPORATION (PM) | 1976-12-21 | — | — | US | disclosed |
| US-3980699-A | ANTIINFLAMMATORY, ANALGESICS, ANTIPYRETIC, ANTIPRURITIC | SYNTEX CORPORATION (PM) | 1976-09-14 | — | — | US | disclosed |
| US-3978124-A | ANALGESIC, ANTIPYRETIC | SYNTEX CORPORATION (PM) | 1976-08-31 | — | — | US | disclosed |
| US-3978116-A | ANALGESIC, ANTIPYRETIC | SYNTEX CORPORATION (PM) | 1976-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | HRH2, HRH1, HRH3 | HSP90AB1 4432/4885GAA 617/4885ALDH1A1 1016/4885 |
| US-20130150407-A1 | PIPERIDINYL NAPHTHYLACETIC ACIDS | HRH2, HRH1, HRH3 | HSP90AB1 3006/4885GAA 1600/4885ALDH1A1 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.